ALGS

Aligos Therapeutics Inc

Add to Watchlist

Advanced Chart

9.130

+0.22(2.469%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.200

Open

9.020

VWAP

8.81

Vol

47.45K

Mkt Cap

55.83M

Low

8.580

Amount

417.97K

EV/EBITDA(TTM)

Total Shares

78.11M

-83.22M

EV/OCF(TTM)

P/S(TTM)

18.75

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

325.00K

-69.37%

325.00K

-74.39%

19.08M

+2932.59%

Estimates Revision

The market is revising Downward the revenue expectations for Aligos Therapeutics, Inc. (ALGS) for FY2025, with the revenue forecasts being adjusted by -91.01% over the past three months. During the same period, the stock price has changed by 67.52%.

Revenue Estimates for FY2025

Revise Downward

-91.01%

In Past 3 Month

Stock Price

Go Up

+67.52%

In Past 3 Month

1 Analyst Rating

294.30% Upside

Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 36.00 USD with a low forecast of 36.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

294.30% Upside

Current: 9.130

Low

36.00

Averages

36.00

High

36.00

294.30% Upside

Current: 9.130

Low

36.00

Averages

36.00

High

36.00

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$70

2025-03-31

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$70

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$75 → $70

2025-03-11

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75 → $70

2025-03-11

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$75

2024-11-07

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75

2024-11-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$75

2024-10-23

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75

2024-10-23

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$75

2024-09-20

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75

2024-09-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Initiates

$75

2024-08-19

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$75

2024-08-19

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aligos Therapeutics Inc (ALGS.O) is -0.90, compared to its 5-year average forward P/E of -3.28. For a more detailed relative valuation and DCF analysis to assess Aligos Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.28

Current PE

-0.90

Overvalued PE

0.61

Undervalued PE

-7.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.46

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.44

Undervalued EV/EBITDA

-12.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

64.18

Current PS

42.90

Overvalued PS

228.62

Undervalued PS

-100.25

Financials

Annual

Quarterly

FY2025Q1

YoY :

-68.46%

311.00K

Total Revenue

FY2025Q1

YoY :

-12.71%

-19.24M

Operating Profit

FY2025Q1

YoY :

-223.59%

43.09M

Net Income after Tax

FY2025Q1

YoY :

-62.19%

-2.11

EPS - Diluted

FY2025Q1

YoY :

-8.17%

-20.95M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+319.51%

-2.42K

FCF Margin - %

FY2025Q1

YoY :

-491.84%

13.85K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 162.3% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

298.7K

Volume

6-9

Months

100.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

200.0K

Volume

Months

6-9

76.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ALGS News & Events

Events Timeline

2025-06-18 (ET)

2025-06-18

08:04:53

Aligos Therapeutics appoints Kieron Wesson as VP, head of CMC

2025-05-20 (ET)

2025-05-20

08:03:23

Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal

2025-05-08 (ET)

2025-05-08

08:18:54

Aligos Therapeutics presents data at EASL Congress 2025

News

5.0

07-11Newsfilter

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5.0

06-18Newsfilter

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

5.0

05-16NASDAQ.COM

Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee

People Also Watch

EBMT

Eagle Bancorp Montana Inc

Northern Technologies International Corp

Quest Resource Holding Corp

Bassett Furniture Industries Inc

Plum Acquisition III Corp

11.000

USD

0.00%

FAQ

What is Aligos Therapeutics Inc (ALGS) stock price today?

The current price of ALGS is 9.13 USD — it has increased 2.47 % in the last trading day.

ALGS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ALGS News & Events

Events Timeline

News

People Also Watch

FAQ

What is Aligos Therapeutics Inc (ALGS) stock price today?

What is Aligos Therapeutics Inc (ALGS)'s business?

What is the price predicton of ALGS Stock?

What is Aligos Therapeutics Inc (ALGS)'s revenue for the last quarter?

What is Aligos Therapeutics Inc (ALGS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Aligos Therapeutics Inc (ALGS)'s fundamentals?

How many employees does Aligos Therapeutics Inc (ALGS). have?

What is Aligos Therapeutics Inc (ALGS) market cap?